Terumo Enhances Coronary Interventional Product Portfolio By Securing Exclusive Global Rights to Orchestra BioMed's Virtue(R) Sirolimus-Eluting Balloon (SEB) through Global Strategic Partnership

First and only non-coated drug-eluting angioplasty balloon that delivers a proprietary bioabsorbable, sustained-release formulation of sirolimus TOKYO, June 13, 2019 -- (Healthcare Sales & Marketing Network) -- Terumo Corporation (TSE: 4543), a leading... Devices, Interventional, Licensing Terumo, Orchestra BioMed, Virtue SEB, Sirolimus, drug eluting balloon
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news